{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:16:13Z","timestamp":1791357373501,"version":"4.3.1"},"reference-count":0,"publisher":"Weston Medical Publishing","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Opioid Management"],"abstract":"<jats:p>Background: Buprenorphine may be safer and better-tolerated than full mu opioid receptor (MOR) agonists. Whether it effectively controls cancer-related pain is unclear. A prior review (Cochrane 2015) did not support prioritizing buprenorphine over full MOR agonists for cancer-associated pain.\nPurpose\/hypothesis: We conducted an updated systematic review of buprenorphine\u2019s effect on cancer-related pain including both new studies and additional study designs\nProcedures\/data\/observations: We searched Cochrane, OVID Medline, EMBASE, EBSCO and Web of Science for studies published in any language up to May 2023 for studies that examined buprenorphine\u2019s impact upon pain severity\/intensity in patients with active cancer. Risk of bias and study quality were assessed using the Cochrane Collaboration tool for randomized controlled trials (RCTs), and the Newcastle-Ottawa Scale for cohort and case-control studies. Data were synthesized using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria.\nConclusions\/applications: 2322 publications were identified and 42 studies were included (14 RCTs , 10 pre-post uncontrolled, 5 cohort, and 2 case-control studies). All had moderate-high risk of bias. One RCT showed buprenorphine was superior to placebo. 11 RCTs (12 papers) showed buprenorphine was as effective as full MOR agonists for cancer pain. 10-30 percent of cancer patients trialing buprenorphine did not achieve adequate response.<\/jats:p>","DOI":"10.5055\/bupe.24.rpj.1075","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T18:35:30Z","timestamp":1727289330000},"page":"B12","source":"Crossref","is-referenced-by-count":4,"title":["Buprenorphine for Cancer Pain: Results from a Systematic Review"],"prefix":"10.5055","volume":"20","author":[{"given":"Maria","family":"Silveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3008","published-online":{"date-parts":[[2024,9,19]]},"container-title":["Journal of Opioid Management"],"original-title":[],"link":[{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/3700\/3986","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/3700\/3986","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T18:35:30Z","timestamp":1727289330000},"score":1,"resource":{"primary":{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/view\/3700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,8,30]]}},"URL":"https:\/\/doi.org\/10.5055\/bupe.24.rpj.1075","relation":{},"ISSN":["1551-7489","1551-7489"],"issn-type":[{"value":"1551-7489","type":"electronic"},{"value":"1551-7489","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,19]]}}}